By: Max Gelman
Bristol Myers Squibb is lifting its 2024 financial guidance for the second straight quarter as CEO Chris Boerner's “transition period” continues.
Max Gelman is a Senior Editor for Endpoints News, a leading biotech and pharmaceutical news platform. With a focus on the healthcare industry, Max covers a wide range of topics including clinical trials, drug development, mergers and acquisitions, and regulatory updates. His articles provide insightful analysis and reporting on the latest developments in the biotech and pharmaceutical sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Max Gelman's articles predominantly cover the healthcare and pharmaceutical industry, with a focus on clinical trials, drug development, and medical research. His coverage heavily relies on cited data and press releases from private sector announcements.
Given Max's reliance on data-driven content, he is likely to be receptive to pitches that offer exclusive access to new findings or insights based on extensive data analysis within the healthcare and pharmaceutical sectors. Additionally, providing expert commentary or analysis of trends in biotech, pharmaceuticals, clinical trials or medical research might also capture his interest.
As Max does not have a specified geographic focus but seems to cover global developments in the industry; therefore sources with an international perspective may resonate well with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .